7WCQ | pdb_00007wcq

Crystal structure of HIV-1 protease in complex with lactam derivative 1


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.01 Å
  • R-Value Free: 
    0.264 (Depositor), 0.264 (DCC) 
  • R-Value Work: 
    0.218 (Depositor), 0.220 (DCC) 
  • R-Value Observed: 
    0.221 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 7WCQ

Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history

Literature

Pocket-to-Lead: Structure-Based De Novo Design of Novel Non-peptidic HIV-1 Protease Inhibitors Using the Ligand Binding Pocket as a Template.

Kojima, E.Iimuro, A.Nakajima, M.Kinuta, H.Asada, N.Sako, Y.Nakata, Z.Uemura, K.Arita, S.Miki, S.Wakasa-Morimoto, C.Tachibana, Y.

(2022) J Med Chem 65: 6157-6170

  • DOI: https://doi.org/10.1021/acs.jmedchem.1c02217
  • Primary Citation Related Structures: 
    7WBS, 7WCQ

  • PubMed Abstract: 

    A novel strategy for lead identification that we have dubbed the "Pocket-to-Lead" strategy is demonstrated using HIV-1 protease as a model target. Sometimes, it is difficult to obtain hit compounds because of the difficulties in satisfying the complex pharmacophoric features. In this study, a virtual fragment hit which does not match all of the pharmacophore features but has key interactions and vectors that could grow into remaining pharmacophore features was optimized in silico . The designed compound 9 demonstrated weak but evident inhibitory activity (IC 50 = 54 μM), and the design concept was proven by the co-crystal structure. Then, structure-based drug design promptly gave compound 14 (IC 50 = 0.0071 μM, EC 50 = 0.86 μM), an almost 10,000-fold improvement in activity from 9 . The structure of the designed molecules proved to be novel with high synthetic feasibility, indicating the usefulness of this strategy to tackle tough targets with complex pharmacophore.


  • Organizational Affiliation
    • Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan.

Macromolecule Content 

  • Total Structure Weight: 11.31 kDa 
  • Atom Count: 810 
  • Modeled Residue Count: 99 
  • Deposited Residue Count: 99 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Protease99Human immunodeficiency virusMutation(s): 0 
UniProt
Find proteins for P12497 (Human immunodeficiency virus type 1 group M subtype B (isolate NY5))
Explore P12497 
Go to UniProtKB:  P12497
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP12497
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
8OC

Query on 8OC



Download:Ideal Coordinates CCD File
B [auth A](3R,4R)-3-[(4-fluorophenyl)methyl]-1-[(4-methoxyphenyl)methyl]-3-(4-methylsulfonylphenyl)-4-oxidanyl-pyrrolidin-2-one
C26 H26 F N O5 S
FNYFCMKBTSFCJY-AZGAKELHSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
8OC BindingDB:  7WCQ IC50: 5.40e+4 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.01 Å
  • R-Value Free:  0.264 (Depositor), 0.264 (DCC) 
  • R-Value Work:  0.218 (Depositor), 0.220 (DCC) 
  • R-Value Observed: 0.221 (Depositor) 
Space Group: P 61 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 62.702α = 90
b = 62.702β = 90
c = 81.75γ = 120
Software Package:
Software NamePurpose
HKL-2000data reduction
HKL-2000data scaling
MOLREPphasing
PHENIXrefinement
PDB_EXTRACTdata extraction

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2022-11-02
    Type: Initial release
  • Version 1.1: 2023-11-29
    Changes: Data collection, Refinement description